Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Bo Didley who wrote (52588)	7/25/1999 11:48:00 AM
From: Wallace Rivers	Read Replies (2) \| Respond to of 120523

What are the terms of the $6 mil. financing with Citadel? Some times, such financings are not particularly healthy for the company and current shareholders.

To: Bo Didley who wrote (52588)	7/25/1999 5:41:00 PM
From: Bill Wexler	Read Replies (1) \| Respond to of 120523

I'm flattered that you seem so obsessed with my analysis of GUMM; however, your threats of a squeeze are ludicrous since you nor anyone else for that matter can make a prediction like that. I stand by my assertion that GUMM is a grossly overvalued stock that has been run up due to the fraudulent promotion of a quack cold remedy. the GUMM stock promotion fraud will eventually, and inevitably, trade significantly lower from these levels - imaginary "short squeeze" or not.

To: Bo Didley who wrote (52588)	7/25/1999 5:53:00 PM
From: out_of_the_loop	Respond to of 120523

Anyone who wants to look at GUMM in depth for a discussion about can go to Wexler's thread and read from #1750 or so. Lots of discussion about Zicam there. Also, correction: the first clinicals are done and have been submitted to the New England Journal of Medicine. These show a p<.001 significance, meaning that there is less than a 1 in 1000 likelihood that the results are from chance alone that Zicam cuts the duration of the common cold from an average of 10-14 days to an average of 1.5 days. Most valid studies need only show p<.01 (five in 100). It is the second group of clinicals that will be done by October.